Yuji Nagatomo1, Dennis M McNamara2, Jeffrey D Alexis3, Leslie T Cooper4, G William Dec5, Daniel F Pauly6, Richard Sheppard7, Randall C Starling8, W H Wilson Tang9. 1. Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio; Sakakibara Heart Institute, Fuchu, Japan. 2. Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 3. University of Rochester Medical Center School of Medicine and Dentistry, Rochester, New York. 4. Mayo Clinic Florida, Jacksonville, Florida. 5. Massachusetts General Hospital, Boston, Massachusetts. 6. Truman Medical Centers, University of Missouri-Kansas City, Kansas City, Missouri. 7. Jewish General Hospital, Montreal, Quebec, Canada. 8. Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio. 9. Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, Ohio. Electronic address: tangw@ccf.org.
Abstract
BACKGROUND: Among various cardiac autoantibodies (AAbs), those recognizing the β1-adrenergic receptor (β1AR) demonstrate agonist-like effects and induce myocardial damage that can be reversed by β-blockers and immunoglobulin G3 (IgG3) immunoadsorption. OBJECTIVES: The goal of this study was to investigate the role of β1AR-AAbs belonging to the IgG3 subclass in patients with recent-onset cardiomyopathy. METHODS:Peripheral blood samples were drawn at enrollment in patients with recent-onset cardiomyopathy (left ventricular ejection fraction [LVEF] ≤0.40; <6 months). The presence of IgG and IgG3-β1AR-AAb was determined, and echocardiograms were assessed, at baseline and 6 months. Patients were followed up for ≤48 months. RESULTS: Among the 353 patients who had blood samples adequate for the analysis, 62 (18%) were positive for IgG3-β1AR-AAbs (IgG3 group), 58 (16%) were positive for IgG but not IgG3 (non-IgG3 group), and the remaining were negative. There were no significant differences in baseline systolic blood pressure, heart rate, or LVEF among the groups at baseline. Left ventricular end-diastolic and end-systolic diameters were significantly larger in the non-IgG3 group compared with the other groups (left ventricular end-diastolic diameter, p < 0.01; left ventricular end-systolic diameter, p = 0.03). At 6 months, LVEF was significantly higher in the IgG3 group (p = 0.007). Multiple regression analysis showed that IgG3-β1AR-AAb was an independent predictor of LVEF at 6 months and change in LVEF over 6 months, even after multivariable adjustment (LVEF at 6 months, β = 0.20, p = 0.01; change in LVEF, β = 0.20, p = 0.008). In patients with high New York Heart Association functional class (III or IV) at baseline, the IgG3 group had a lower incidence of the composite endpoint of all-cause death, cardiac transplantation, and hospitalization due to heart failure, whereas the non-IgG3 group had the highest incidence of the composite endpoint. CONCLUSIONS:IgG3-β1AR-AAbs were associated with more favorable myocardial recovery in patients with recent-onset cardiomyopathy. Copyright Â
RCT Entities:
BACKGROUND: Among various cardiac autoantibodies (AAbs), those recognizing the β1-adrenergic receptor (β1AR) demonstrate agonist-like effects and induce myocardial damage that can be reversed by β-blockers and immunoglobulin G3 (IgG3) immunoadsorption. OBJECTIVES: The goal of this study was to investigate the role of β1AR-AAbs belonging to the IgG3 subclass in patients with recent-onset cardiomyopathy. METHODS: Peripheral blood samples were drawn at enrollment in patients with recent-onset cardiomyopathy (left ventricular ejection fraction [LVEF] ≤0.40; <6 months). The presence of IgG and IgG3-β1AR-AAb was determined, and echocardiograms were assessed, at baseline and 6 months. Patients were followed up for ≤48 months. RESULTS: Among the 353 patients who had blood samples adequate for the analysis, 62 (18%) were positive for IgG3-β1AR-AAbs (IgG3 group), 58 (16%) were positive for IgG but not IgG3 (non-IgG3 group), and the remaining were negative. There were no significant differences in baseline systolic blood pressure, heart rate, or LVEF among the groups at baseline. Left ventricular end-diastolic and end-systolic diameters were significantly larger in the non-IgG3 group compared with the other groups (left ventricular end-diastolic diameter, p < 0.01; left ventricular end-systolic diameter, p = 0.03). At 6 months, LVEF was significantly higher in the IgG3 group (p = 0.007). Multiple regression analysis showed that IgG3-β1AR-AAb was an independent predictor of LVEF at 6 months and change in LVEF over 6 months, even after multivariable adjustment (LVEF at 6 months, β = 0.20, p = 0.01; change in LVEF, β = 0.20, p = 0.008). In patients with high New York Heart Association functional class (III or IV) at baseline, the IgG3 group had a lower incidence of the composite endpoint of all-cause death, cardiac transplantation, and hospitalization due to heart failure, whereas the non-IgG3 group had the highest incidence of the composite endpoint. CONCLUSIONS:IgG3-β1AR-AAbs were associated with more favorable myocardial recovery in patients with recent-onset cardiomyopathy. Copyright Â
Authors: J W Mason; J B O'Connell; A Herskowitz; N R Rose; B M McManus; M E Billingham; T E Moon Journal: N Engl J Med Date: 1995-08-03 Impact factor: 91.245
Authors: Alexander Staudt; Yvonne Staudt; Marcus Dörr; Marco Böhm; Fabian Knebel; Astrid Hummel; Lydia Wunderle; Malte Tiburcy; Klaus D Wernecke; Gert Baumann; Stephan B Felix Journal: J Am Coll Cardiol Date: 2004-08-18 Impact factor: 24.094
Authors: Beatrice Bornholz; Stefanie Weidtkamp-Peters; Stephanie Schmitmeier; Claus A M Seidel; Lars R Herda; Stephan B Felix; Horst Lemoine; Jürgen Hescheler; Filomain Nguemo; Christoph Schäfer; Morten O Christensen; Christian Mielke; Fritz Boege Journal: Cardiovasc Res Date: 2012-12-03 Impact factor: 10.787
Authors: Maradumane L Mohan; Yuji Nagatomo; Prasenjit Prasad Saha; Sromona D Mukherjee; Timothy Engelman; Rommel Morales; Stanley L Hazen; W H Wilson Tang; Sathyamangla V Naga Prasad Journal: Mol Biol Cell Date: 2021-02-03 Impact factor: 4.138
Authors: Katrin Wenzel; Sarah Schulze-Rothe; Johannes Müller; Gerd Wallukat; Annekathrin Haberland Journal: PLoS One Date: 2018-02-09 Impact factor: 3.240
Authors: Diana Ernst; Johan Westerbergh; Georgios Sogkas; Alexandra Jablonka; Gerrit Ahrenstorf; Reinhold Ernst Schmidt; Harald Heidecke; Lars Wallentin; Gabriela Riemekasten; Torsten Witte Journal: Sci Rep Date: 2019-10-10 Impact factor: 4.379
Authors: Eli F Kelley; Troy J Cross; Craig M McDonald; Cinrg Investigators; Eric P Hoffman; Christopher F Spurney; Luca Bello Journal: Clin Med Insights Cardiol Date: 2022-08-23